Functional antibody characterization via direct structural analysis and information-driven protein-protein docking.

Area of Science:

• Immunology
• Computational Biology
• Structural Biology

Background:

• Understanding therapeutic antibody mechanisms is crucial for drug development.
• KD035 is a fully human antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2).
• KD035 inhibits VEGF-A and VEGF-C mediated VEGFR2 activation.

Purpose of the Study:

• To create a computational model of the complex between KD035 variable fragment (KD035(Fv)) and VEGFR2 domains 2 and 3 (VEGFR2(D2-3)).
• To provide a validated in silico method for antibody-antigen complex modeling.

Main Methods:

• Utilized experimental data including X-ray structures, binding assays, and domain mapping to guide computational modeling.
• Employed molecular dynamics simulations to assess model accuracy.
• Validated the model through mutagenesis and binding analysis.

Main Results:

• A computational model of the KD035(Fv)-VEGFR2(D2-3) complex was successfully generated.
• The model's accuracy was confirmed through simulations and experimental validation.
• The methodology provides a robust framework for future protein-protein complex modeling.

Conclusions:

• The developed computational model accurately represents the KD035-VEGFR2 interaction.
• This in silico approach offers a valuable tool for characterizing therapeutic antibodies.
• The established modeling strategy can be applied to other antibody-antigen systems and protein complexes.